Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Eisai Stories

2013-11-07 16:31:39

-- Arena and Eisai Expand Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) to Include Most Countries Worldwide -- SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2013. Arena has also rescheduled its conference call and webcast to tomorrow, November 8, 2013, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). "We are excited by our expanded...

2013-11-07 16:31:09

-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications -- SAN DIEGO, Calif. and WOODCLIFF LAKE, N.J., Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ(®) (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its parent company Eisai...

2013-11-01 08:27:25

Award supports vital research to understand rare and severe form of epilepsy WOODCLIFF LAKE, N.J., Nov. 1, 2013 /PRNewswire/ -- The Child Neurology Foundation (CNF) and Eisai Inc. today announced that the first annual Michael SanInocencio Lennox-Gastaut Syndrome (LGS) Research Award was presented to Maura Madou, MD, Child Neurology Fellow at University of California - San Francisco, Benioff Children's Hospital, to facilitate her research on LGS. Dr. Madou will receive a $30,000 grant...

2013-10-29 00:21:49

FIRST SHIPMENT TO BENEFIT MORE THAN 6 MILLION PEOPLE IN 4 ENDEMIC COUNTRIES WOODCLIFF LAKE, N.J., Oct. 28, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has begun the free supply of diethylcarbamazine citrate (DEC) 100 mg tablets produced at its Vizag Plant in India to the World Health Organization (WHO) in line with its commitment to help WHO in its global effort to eliminate lymphatic filariasis in...

2013-10-16 23:23:04

Reportbuyer.com just published a new market research report: Alzheimer’s Disease Therapeutics and Diagnostics: World Market 2013-2023. London (PRWEB) October 16, 2013 Alzheimer's medicine - your guide to technologies, trends and revenues Where's treatment of Alzheimer's disease heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities,...

2013-10-15 08:33:21

Expansion to Approximately 400 Sales Specialists Follows Increased Coverage of BELVIQ by Health Plans and Pharmacy Benefit Managers SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. will increase its BELVIQ(®) sales force to approximately 400 representatives by December 2013, doubling the size of the sales force from when BELVIQ became available in June 2013. The expansion of the sales force, which has commenced and follows...

2013-10-15 08:33:08

BELVIQ® Sales Force to Double in Size by December 2013 WOODCLIFF LAKE, N.J., Oct. 15, 2013 /PRNewswire/ -- Eisai Inc. announced today that, as part of its long-term marketing strategy, the company will expand its sales force by adding more than 200 new contract sales representatives to its Specialty Business Unit. The representatives will focus on educating healthcare providers in the United States about BELVIQ(®), and will bring the total sales force to approximately 400 by December,...

2013-10-09 08:29:03

EXTON, Pa., Oct. 9, 2013 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1 clinical study with MORAb-004 in pediatric patients with relapsed/refractory solid tumors. The open-label Phase 1 study will assess the safety, tolerability and pharmacokinetics of MORAb-004 administered in weekly intravenous infusions in pediatric patients. MORAb-004 is an investigational monoclonal...

2013-10-01 12:29:36

LUGANO, Switzerland, October 1, 2013 /PRNewswire/ -- The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi(R) (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The establishment of this...

2013-10-01 08:31:05

Eisai, CancerCare®, and Cancer Support Community(SM) Launch meal Trains(SM) sponsored by Magnolia(TM) During Breast Cancer Awareness Month; Campaign Aims to Drive 1,000 New meal Trains in October WOODCLIFF LAKE, N.J., Oct. 1, 2013 /PRNewswire/ -- Eisai Inc., along with collaborators CancerCare and Cancer Support Community, have announced meal Trains(SM) sponsored by Magnolia(TM), which aim to broaden the positive impact of providing meals to patients living with breast cancer and...